Literature DB >> 10467924

Spinal cannabinoids are anti-allodynic in rats with persistent inflammation.

William J Martin1, Carole M Loo, Allan I Basbaum.   

Abstract

Cannabinoid receptor (CB1) agonists strongly inhibit behavioral responses to acute noxious stimuli, but their effects on behavioral responses in persistent pain states are less clear. Here, we examined the effects of intrathecal (i.t.) administration of a CB1 agonist, WIN55,212-2, on mechanical allodynia (decreased withdrawal threshold) produced by injections of complete Freund's adjuvant (CFA) in the plantar surface of the rat hindpaw. We measured mechanical thresholds with calibrated von Frey filaments before and after CFA and used Fos expression as a marker of the activity of spinal cord neurons during inflammation and in response to a CB1 antagonist. One day post CFA-induced injury, mechanical sensitivity was significantly increased in the hindpaw ipsilateral to the CFA injection, as was the number of neurons that express Fos. Intrathecal injection of WIN55,212-2, significantly, reversed the allodynia at doses that had no effect on the mechanical threshold of the contralateral paw of CFA-treated or the withdrawal thresholds in naive animals. This effect was blocked by coadministration of the CB1 antagonist, SR141716A, with WIN55212-2. By itself, SR141716A, had no effect on mechanical thresholds in normal animals. In inflamed animals, SR141716A did not further reduce mechanical thresholds in the inflamed paw, but it significantly enhanced mechanical sensitivity 'contralateral' to the inflammation. Furthermore, i.t. injection of SR141716A increased Fos expression in both normal and inflamed animals, to a different extent in different laminae. In normal animals, the increase was primarily in laminae V-VI and in the ventral horn; in animals with persistent inflammation SR141716A increased the number of Fos neurons in laminae I-II and V-VI. These results demonstrate that WIN55212-2 reverses inflammation-induced allodynia at doses that do not produce analgesia and that SR141716A differentially affects the pattern of Fos expression in the spinal cord, depending on the presence or absence of inflammation. Taken together, these results suggest that the CB1 receptor system is tonically active in the spinal cord under normal conditions and that its activity is increased in response to injury.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10467924     DOI: 10.1016/S0304-3959(99)00045-7

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  31 in total

1.  Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Pharmacol Biochem Behav       Date:  2011-09-17       Impact factor: 3.533

Review 2.  Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review.

Authors:  F A Campbell; M R Tramèr; D Carroll; D J Reynolds; R A Moore; H J McQuay
Journal:  BMJ       Date:  2001-07-07

3.  Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia.

Authors:  Darryl T Hamamoto; Subhalakshmi Giridharagopalan; Donald A Simone
Journal:  Eur J Pharmacol       Date:  2006-12-09       Impact factor: 4.432

Review 4.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Metabotropic glutamate and cannabinoid receptor crosstalk in periaqueductal grey pain processing.

Authors:  E Palazzos; V de Novellis; I Marabese; F Rossi; S Maione
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

Review 6.  Role of cannabinoids in the management of neuropathic pain.

Authors:  M Isabel Martín Fontelles; Carlos Goicoechea García
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Brain Res       Date:  2011-07-26       Impact factor: 3.252

Review 8.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

9.  Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.

Authors:  Farinaz Nasirinezhad; Stanislava Jergova; James P Pearson; Jacqueline Sagen
Journal:  Neuropharmacology       Date:  2014-12-05       Impact factor: 5.250

10.  Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.

Authors:  Kristina B Svendsen; Troels S Jensen; Flemming W Bach
Journal:  BMJ       Date:  2004-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.